^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3461 - Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer
Published date:
03/15/2023
Excerpt:
Among a panel of KRAS mt NSCLC cell lines, avutometinib + everolimus showed synergistic anti-proliferative activity across KRAS G12C, G12V and G12D variants (mean synergy score of ~18). In the H441 KRAS G12V NSCLC xenograft model, there was a significant reduction in tumor volume and increase in survival with the combination of avutometinib and everolimus (87% TGI; 66 days vs 36.5 days in control group) compared to control....We have shown that avutometinib and everolimus induce synergistic anti-tumor effects preclinically...with KRAS mt NSCLC including non-G12C variants.
Secondary therapy:
everolimus
